What To-be-discard Biomaterials From ART Cycles Can Tell us About the Treatment Cycle Outcome?
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: IVF, Infertility. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Various to-be-discard material from IVF treatment cycle will be collect and examined, aiming to identify potential reasons of successful outcome or cycle failure.
Detailed description
Usually around 2/3 of IVF material will be discarded at the end of each treatment cycle, including immature oocytes, abnormal fertilized zygotes, poor grading embryos, spent culture medium, etc. Next generation sequencing will be performed for DNA / RNA analysis including the length and the quantity, RNA-seq will be applied for transcriptome profiling, and protein profile will be investigated in a pool sample. By applying various diagnostic tools against those to-be-discard biomaterials, we aim to identify potential underlying reasons of indicating either for an IVF failure or a successful cycle, and try to develop a non-invasive testing method for embryo quality check; better detection of the embryo implantation potential and eventually further increase the IVF clinical outcome.
Primary outcome measures
- DNA/RNA sequencing data [Time frame: Through study completion, around 3 year]
- Proteomic profile [Time frame: Through study completion, around 3 year]
Secondary outcome measures (3)
- Blastocyst formation rate [Time frame: 5 days after fertilization]
- Clinical pregnancy rate [Time frame: Around 5 weeks after embryo transfer]
- Live birth rate [Time frame: Around 9 months after embryo transfer]
Eligibility criteria
Inclusion criteria
- Patients attending the Assisted Reproductive Technology (ART) Unit of the Chinese University of Hong Kong for ART treatment.
- Participant able to give voluntary, written, informed consent to participate in the study.
Exclusion criteria
- Patient using donor gamete in IVF treatment
- Patient refuses to join and failed to giving consent for any reasons
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Other
Study locations
Hong Kong · 1 center
- The Chinese University of Hong Kong and Prince of Wales Hospital — Hong Kong
Identifiers
NCT: NCT06021340 · 2023.066